References

1. Gump, B.B.; Matthews, K.A.; Eberly, L.E.; Chang, Y.F. Depressive symptoms and mortality in men: Results from the Multiple Risk Factor Intervention Trial. Stroke 2005, 36, 98–102.
2. Kessler, R.C. Prevalence and Effects of Mood Disorders on Work Performance in a Nationally Representative Sample of U.S. Workers. Am. J. Psychiatry 2006, 163, 1561–1568.
3. Irwin, M.R.; Miller, A.H. Depressive disorders and immunity: 20 years of progress and discovery. Brain Behav. Immun. 2007, 21, 374–383.
4. Szelényi, J. Cytokines and the central nervous system. Brain Res. Bull. 2001, 54, 329–338.
5. Dowlati, Y.; Herrmann, N.; Swardfager, W.; Liu, H.; Sham, L.; Reim, E.K.; Lanctôt, K.L. A Meta-Analysis of Cytokines in Major Depression. Biol. Psychiatry 2010, 67, 446–457.
6. Swardfager, W.; Lanctôt, K.; Rothenburg, L.; Wong, A.; Cappell, J.; Herrmann, N. A meta-analysis of cytokines in Alzheimer’s disease. Biol. Psychiatry 2010, 68, 930–941.
7. Tran, B.X.; McIntyre, R.S.; Latkin, C.A.; Phan, H.T.; Vu, G.T.; Nguyen HL, T.; Ho, R. The current research landscape on the artificial intelligence application in the management of depressive disorders: A bibliometric analysis. Int. J. Environ. Res. Public Health 2019, 16, 2150.
8. Sidey-Gibbons, J.A.M.; Sidey-Gibbons, C.J. Machine learning in medicine: A practical introduction. BMC Med. Res. Methodol. 2019, 19, 1–18.
9. Dantzer, R.; Aubert, A.; Bluthé, R.-M.; Gheusi, G.; Cremona, S.; Layé, S.; Konsman, J.-P.; Parnet, P.; Kelley, K.W. Mechanisms of the Behavioural Effects of Cytokines. In Advances in Experimental Medicine and Biology; Springer Nature: London, UK, 1999; pp. 83–105.
10. Xia, Z.; DePIERRE, J.W.; Nässberger, L. Tricyclic antidepressants inhibit IL-6, IL-1β and TNF-α release in human blood monocytes and IL-2 and interferon-γ in T cells. Immunopharmacology 1996, 34, 27–37.
11. Hannestad, J.; DellaGioia, N.; Bloch, M. The effect of antidepressant medication treatment on serum levels of inflammatory cytokines: A meta-analysis. Neuropsychopharmacology 2011, 36, 2452–2459.
12. Munzer, A.; Sack, U.; Mergl, R.; Schönherr, J.; Petersein, C.; Bartsch, S.; Kirkby, K.C.; Bauer, K.; Himmerich, H. Impact of Antidepressants on Cytokine Production of Depressed Patients in Vitro. Toxins 2013, 5, 2227–2240.
13. Więdłocha, M.; Marcinowicz, P.; Krupa, R.; Janoska-Jaździk, M.; Janus, M.; Dębowska, W.; Mosiołek, A.; Waszkiewicz, N.; Szulc, A. Effect of antidepressant treatment on peripheral inflammation markers—A meta-analysis. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2018, 80, 217–226.
14. Kern, S.; Skoog, I.; Börjesson-Hanson, A.; Blennow, K.; Zetterberg, H.; Östling, S.; Kern, J.; Gudmundsson, P.; Marlow, T.; Rosengren, L.; et al. Higher CSF interleukin-6 and CSF interleukin-8 in current depression in older women. Results from a population-based sample. Brainbehav. Immun. 2014, 41, 55–58.
15. Köhler, C.A.; Freitas, T.H.; Stubbs, B.; Maes, M.; Solmi, M.; Veronese, N.; Carvalho, A.F. Peripheral alterations in cytokine and chemokine levels after antidepressant drug treatment for major depressive disorder: Systematic review and meta-analysis. Mol. Neurobiol. 2018, 55, 4195–4206.
16. Brymer, K.J.; Romay-Tallon, R.; Allen, J.; Caruncho, H.J.; Kalynchuk, L.E. Exploring the Potential Antidepressant Mechanisms of TNFα Antagonists. Front. Neurosci. 2019, 13, 98.
17. Pinto, E.F.; Andrade, C. Interferon-Related Depression: A Primer on Mechanisms, Treatment, and Prevention of a Common Clinical Problem. Curr. Neuropharmacol. 2016, 14, 743–748.
18. Tyring, S.; Gottlieb, A.; Papp, K.; Gordon, K.; Leonardi, C.; Wang, A.; Lalla, D.; Woolley, M.; Jahreis, A.; Zitnik, R.; et al. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: Double-blind placebo-controlled randomised phase III trial. Lancet 2006, 367, 29–35.
19. Gupta, R.; Gupta, K.; Tripathi, A.K.; Bhatia, M.S.; Gupta, L.K. Effect of mirtazapine treatment on serum levels of brain-derived neurotrophic factor and tumor necrosis factor-α in patients of major depressive disorder with severe depression. Pharmacology 2016, 97, 184–188.
20. Kast, R.E. Anti-and pro-inflammatory considerations in antidepressant use during medical illness: Bupropion lowers and mirtazapine increases circulating tumor necrosis factor-alpha levels. Gen. Hosp. Psychiatry 2003, 25, 495–496.
21. Kraus, T.; Haack, M.; Schuld, A.; Hinze-Selch, D.; Koethe, D.; Pollmächer, T. Body Weight, the Tumor Necrosis Factor System, and Leptin Production during Treatment with Mirtazapine or Venlafaxine. Pharmacopsychiatry 2002, 35, 220–225.
22. Maes, M.; Song, C.; Lin, A.-H.; Bonaccorso, S.; Kenis, G.; De Jongh, R.; Bosmans, E.; Scharpé, S. Negative Immunoregulatory Effects of Antidepressants Inhibition of Interferon-γ and Stimulation of Interleukin-10 Secretion. Neuropsychopharmacology 1999, 20, 370–379.
23. Meyers, C.A. Mood and Cognitive Disorders in Cancer Patients Receiving Cytokine Therapy. In Advances in Experimental Medicine and Biology; Springer Nature: London, UK, 1999; Volume 461, pp. 75–81.
24. Smith, R. The macrophage theory of depression. Med. Hypotheses 1991, 35, 298–306.
25. Maes, M. Major Depression and Activation of The Inflammatory Response System. In Advances in Experimental Medicine and Biology; Springer Science and Business Media LLC: Berlin, Germany, 1999; Volume 461, pp. 25–46.
26. Lindemann, R.A. The regulatory effects of monocytes on human natural killer cells activated by lipopolysaccharides. J. Periodontal Res. 1991, 26, 486–490.
27. Mayer, P.; Geissler, K.; Valent, P.; Ceska, M.; Bettelheim, P.; Liehl, E. Recombinant human interleukin 6 is a potent inducer of the acute phase response and elevates the blood platelets in nonhuman primates. Exp. Hematol. 1991, 19, 688–696.
28. D’Acunto, G.; Nageye, F.; Zhang, J.; Masi, G.; Cortese, S. Inflammatory Cytokines in Children and Adolescents with Depressive Disorders: A Systematic Review and Meta-Analysis. J. Child Adolesc. Psychopharmacol. 2019, 29, 362–369.
29. Brambilla, F.; Monteleone, P.; Maj, M. Interleukin-1β and tumor necrosis factor-α in children with major depressive disorder or dysthymia. J. Affect. Disord. 2004, 78, 273–277.
30. Schröcksnadel, K.; Wirleitner, B.; Winkler, C.; Fuchs, D. Monitoring tryptophan metabolism in chronic immune activation. Clin. Chim. Acta 2006, 364, 82–90.
31. Mellor, A.L.; Munn, D.H. Tryptophan catabolism and T-cell tolerance: Immunosuppression by starvation? Immunol. Today 1999, 20, 469–473.
32. Ruhe, H.G.; Mason, N.S.; Schene, A.H. Mood is indirectly related to serotonin, norepinephrine and dopamine levels in humans: A meta-analysis of monoamine depletion studies. Mol. Psychiatry 2007, 12, 331–359.
33. Maes, M.; Wauters, A.; Verkerk, R.; Demedts, P.; Neels, H.; Van Gastel, A.; Cosyns, P.; Scharpé, S.; DeSnyder, R. Lower Serum L-Tryptophan Availability in Depression as a Marker of a More Generalized Disorder in Protein Metabolism. Neuropsychopharmacology 1996, 15, 243–251.
34. O’Connor, J.; Lawson, M.; André, C.; Moreau, M.; Lestage, J.; Castanon, N.; Kelley, K.; Dantzer, R. Lipopolysaccharide-induced depressive-like behavior is mediated by indoleamine 2,3-dioxygenase activation in mice. Mol. Psychiatry 2008, 14, 511–522.
35. Schwarcz, R.; O Whetsell, W.; Mangano, R.M. Quinolinic acid: An endogenous metabolite that produces axon-sparing lesions in rat brain. Science 1983, 219, 316–318.
36. Kitagami, T.; Yamada, K.; Miura, H.; Hashimoto, R.; Nabeshima, T.; Ohta, T. Mechanism of systemically injected interferon-alpha impeding monoamine biosynthesis in rats: Role of nitric oxide as a signal crossing the blood–brain barrier. Brain Res. 2003, 978, 104–114.
37. Miller, A.H.; Maletic, V.; Raison, C.L. Inflammation and Its Discontents: The Role of Cytokines in the Pathophysiology of Major Depression. Biol. Psychiatry 2009, 65, 732–741.
38. Mufaddel, A.; Omer, A.A.; Salem, M.O. Psychiatric Aspects of Infectious Diseases. Open J. Psychiatry 2014, 4, 202–217.
39. Pace, T.W.; Hu, F.; Miller, A.H. Cytokine-effects on glucocorticoid receptor function: Relevance to glucocorticoid resistance and the pathophysiology and treatment of major depression. Brain Behav. Immun. 2007, 21, 9–19.
40. Miller, E.S.; Sakowicz, A.; Roy, A.; Yang, A.; Sullivan, J.T.; Grobman, W.A.; Wisner, K.L. Plasma and cerebrospinal fluid inflammatory cytokines in perinatal depression. Am. J. Obstet. Gynecol. 2019, 220, 271.e1–271.e10.
41. Engler, H.; Brendt, P.; Wischermann, J.; Wegner, A.; Röhling, R.; Schoemberg, T.; Meyer, U.; Gold, R.; Peters, J.; Benson, S.; et al. Selective increase of cerebrospinal fluid IL-6 during experimental systemic inflammation in humans: Association with depressive symptoms. Mol. Psychiatry 2017, 22, 1448–1454.
42. Lindqvist, D.; Janelidze, S.; Hagell, P.; Erhardt, S.; Samuelsson, M.; Minthon, L.; Hansson, O.; Björkqvist, M.; Träskman-Bendz, L.; Brundin, L. Interleukin-6 Is Elevated in the Cerebrospinal Fluid of Suicide Attempters and Related to Symptom Severity. Biol. Psychiatry 2009, 66, 287–292.
43. Carpenter, L.L.; Heninger, G.R.; Malison, R.T.; Tyrka, A.R.; Price, L.H. Cerebrospinal fluid interleukin (IL)-6 in unipolar major depression. J. Affect. Disord. 2004, 79, 285–289.
44. Wang, A.K.; Miller, B.J. Meta-analysis of cerebrospinal fluid cytokine and tryptophan catabolite alterations in psy-chiatric patients: Comparisons between schizophrenia, bipolar disorder, and depression. Schizophr. Bull. 2018, 44, 75–83.
45. Kowalczyk, M.; Szemraj, J.; Bliźniewska, K.; Maes, M.; Berk, M.; Su, K.-P.; Gałecki, P. An immune gate of depression—Early neuroimmune development in the formation of the underlying depressive disorder. Pharmacol. Rep. 2019, 71, 1299–1307.
46. Gustafsson, H.C.; Sullivan, E.L.; Nousen, E.K.; Sullivan, C.A.; Huang, E.; Rincon, M.; Nigg, J.T.; Loftis, J.M. Maternal prenatal depression predicts infant negative affect via maternal inflammatory cytokine levels. Brain Behav. Immun. 2018, 73, 470–481.
47. De Craen, A.J.M.; Posthuma, D.; Remarque, E.J.; Biggelaar, A.H.J.V.D.; Westendorp, R.G.J.; I Boomsma, D. Heritability estimates of innate immunity: An extended twin study. Genes Immun. 2005, 6, 167–170.
48. Bufalino, C.; Hepgul, N.; Aguglia, E.; Pariante, C.M. The role of immune genes in the association between depression and inflammation: A review of recent clinical studies. Brain Behav. Immun. 2013, 31, 31–47.
49. Mill, J.; Wigg, K.; Burcescu, I.; Vetro, Á.; Kiss, E.; Kapornai, K.; Tamás, Z.; Baji, I.; Gádoros, J.; Kennedy, J.; et al. Mutation screen and association analysis of the glucocorticoid receptor gene (NR3C1) in childhood-onset mood disorders (COMD). Am. J. Med. Genet. Part B Neuropsychiatr. Genet. 2009, 150, 866–873.
50. Szczepankiewicz, A.; Leszczyńska-Rodziewicz, A.; Pawlak, J.; Rajewska-Rager, A.; Dmitrzak-Weglarz, M.; Wilkosc, M.; Skibinska, M.; Hauser, J. Glucocorticoid receptor polymorphism is associated with major depression and predominance of depression in the course of bipolar disorder. J. Affect. Disord. 2011, 134, 138–144.
51. Deinzer, R.; Granrath, N.; Stuhl, H.; Twork, L.; Idel, H.; Waschul, B.; Herforth, A. Acute stress effects on local Il-1β responses to pathogens in a human in vivo model. Brainbehav. Immun. 2004, 18, 458–467.
52. A O’Connor, K.; Johnson, J.D.; Hansen, M.K.; Frank, J.L.W.; Maksimova, E.; Watkins, L.R.; Maier, S.F. Peripheral and central proinflammatory cytokine response to a severe acute stressor. Brain Res. 2003, 991, 123–132.
53. McDade, T.W.; Hawkley, L.C.; Cacioppo, J.T. Psychosocial and Behavioral Predictors of Inflammation in Middle-Aged and Older Adults: The Chicago Health, Aging, and Social Relations Study. Psychosom. Med. 2006, 68, 376–381.
54. Kiecolt-Glaser, J.K.; Loving, T.J.; Stowell, J.R.; Malarkey, W.B.; Lemeshow, S.; Dickinson, S.L.; Glaser, R. Hostile Marital Interactions, Proinflammatory Cytokine Production, and Wound Healing. Arch. Gen. Psychiatry 2005, 62, 1377–1384.
55. Miller, G.E.; Chen, E.; Sze, J.; Marin, T.; Arevalo, J.M.; Doll, R.; Cole, S.W. A functional genomic fingerprint of chronic stress in humans: Blunted glucocorticoid and increased NF-κB signaling. Biol. Psychiatry 2008, 64, 266–272.
56. Lee, H.; Song, M.; Lee, J.; Kim, J.-B.; Lee, M.-S. Prospective study on cytokine levels in medication-naïve adolescents with first-episode major depressive disorder. J. Affect. Disord. 2020, 266, 57–62.
57. Amitai, M.; Taler, M.; Carmel, M.; Michaelovsky, E.; Eilat, T.; Yablonski, M.; Orpaz, N.; Chen, A.; Apter, A.; Weizman, A.; et al. The Relationship Between Plasma Cytokine Levels and Response to Selective Serotonin Reuptake Inhibitor Treatment in Children and Adolescents with Depression and/or Anxiety Disorders. J. Child Adolesc. Psychopharmacol. 2016, 26, 727–732.
58. Pérez-Sánchez, G.; Becerril-Villanueva, E.; Arreola, R.; Martínez-Levy, G.; Hernández-Gutiérrez, M.E.; Velasco-Velázquez, M.; Alvarez-Herrera, S.; Cruz-Fuentes, C.; Palacios, L.; De La Peña, F.; et al. Inflammatory Profiles in Depressed Adolescents Treated with Fluoxetine: An 8-Week Follow-up Open Study. Mediat. Inflamm. 2018, 2018, 1–12.
59. Himmerich, H.; Koethe, D.; Schuld, A.; Yassouridis, A. Plasma levels of leptin and endogenous immune modulators during treatment with carbamazepine or lithium. Psychopharmacology 2004, 179, 447–451.
60. Kluge, M.; Schuld, A.; Schacht, A.; Himmerich, H.; Dalal, M.A.; Wehmeier, P.M.; Hinze-Selch, D.; Kraus, T.; Dittmann, R.W.; Pollmächer, T. Effects of clozapine and olanzapine on cytokine systems are closely linked to weight gain and drug-induced fever. Psychoneuroendocrinology 2009, 34, 118–128.
61. Jha, M.K.; Minhajuddin, A.; Gadad, B.S.; Greer, T.L.; Mayes, T.L.; Trivedi, M.H. Interleukin 17 selectively predicts better outcomes with bupropion-SSRI combination: Novel T cell biomarker for antidepressant medication selection. Brain Behav. Immun. 2017, 66, 103–110.
62. Maas, D.W.; Westendorp, R.G.; Willems, J.M.; de Craen, A.J.; van der Mast, R.C. TNF-α antagonist infliximab in the treatment of depression in older adults: Results of a prematurely ended, randomized, placebo-controlled trial. J. Clin. Psychopharmacol. 2010, 30, 343–345.
63. Raison, C.L.; Rutherford, R.E.; Woolwine, B.J.; Shuo, C.; Schettler, P.; Drake, D.F.; Miller, A.H. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: The role of baseline inflammatory biomarkers. JAMA Psychiatry 2013, 70, 31–41.
64. Wu, C.-Y.; Chang, Y.-T.; Juan, C.-K.; Shen, J.-L.; Lin, Y.-P.; Shieh, J.-J.; Liu, H.-N.; Chen, Y.-J. Depression and Insomnia in Patients With Psoriasis and Psoriatic Arthritis Taking Tumor Necrosis Factor Antagonists. Medicine 2016, 95, e3816.
65. Zhou, A.J.; Lee, Y.; Salvadore, G.; Hsu, B.; Fonseka, T.M.; Kennedy, S.H.; McIntyre, R.S. Sirukumab: A Potential Treatment for Mood Disorders? Adv. Ther. 2017, 34, 78–90.
66. Silva, G.D.G.D.; Wiener, C.D.; Barbosa, L.P.; Araújo, J.M.G.; Molina, M.L.; Martin, P.S.; Oses, J.P.; Jansen, K.; Souza, L.D.D.M.; Da Silva, R.A. Pro-inflammatory cytokines and psychotherapy in depression: Results from a randomized clinical trial. J. Psychiatr. Res. 2016, 75, 57–64.
67. Kéri, S.; Szabó, C.; Kelemen, O. Expression of Toll-Like Receptors in peripheral blood mononuclear cells and response to cognitive-behavioral therapy in major depressive disorder. Brain Behav. Immun. 2014, 40, 235–243.
68. Gazal, M.; Souza, L.D.; Fucolo, B.A.; Wiener, C.D.; Silva, R.A.; Pinheiro, R.T.; Jansen, K.; Ghislene, G.; Oses, J.P.; Kaster, M.P. The impact of cognitive behavioral therapy on IL-6 levels in unmedicated women experiencing the first episode of depression: A pilot study. Psychiatry Res. 2013, 209, 742–745.
69. Zautra, A.J.; Davis, M.C.; Reich, J.W.; Nicassario, P.; Tennen, H.; Finan, P.; Kratz, A.; Parrish, B.; Irwin, M.R. Comparison of cognitive behavioral and mindfulness meditation interventions on adaptation to rheumatoid arthritis for patients with and without history of recurrent depression. J. Consult. Clin. Psychol. 2008, 76, 408–421.
70. Bower, J.E.; Greendale, G.; Crosswell, A.D.; Garet, D.; Sternlieb, B.; Ganz, P.A.; Irwin, M.R.; Olmstead, R.; Arevalo, J.; Cole, S.W. Yoga reduces inflammatory signaling in fatigued breast cancer survivors: A randomized controlled trial. Psychoneuroendocrinology 2014, 43, 20–29.
71. Kiecolt-Glaser, J.K.; Bennett, J.M.; Andridge, R.; Peng, J.; Shapiro, C.L.; Malarkey, W.B.; Emery, C.F.; Layman, R.; Mrozek, E.E.; Glaser, R. Yoga’s Impact on Inflammation, Mood, and Fatigue in Breast Cancer Survivors: A Randomized Controlled Trial. J. Clin. Oncol. 2014, 32, 1040–1049.
72. Cryan, J.F.; Dinan, T.G. Mind-altering microorganisms: The impact of the gut microbiota on brain and behaviour. Nat. Rev. Neurosci. 2012, 13, 701–712.
73. Mass, M.; Kubera, M.; Leunis, J.C. The gut-brain barrier in major depression: Intestinal mucosal dysfunction with an increased translocation of LPS from gram negative enterobacteria (leaky gut) plays a role in the inflammatory pathophysiology of depression. Neuroendocrinol. Lett. 2008, 29, 117–124.
74. Koopman, M.; El Aidy, S. Depressed gut? The microbiota-diet-inflammation trialogue in depression. Curr. Opin. Psychiatry 2017, 30, 369–377.
75. Dinan, T.G.; Stanton, C.; Cryan, J.F. Psychobiotics: A Novel Class of Psychotropic. Biol. Psychiatry 2013, 74, 720–726.
76. Esposito, K.; Marfella, R.; Ciotola, M. Effect of a Mediterranean-style diet on endothelial dysfunction and markers of vascular inflammation in the metabolic syndrome. A randomized trial. ACC Curr. J. Rev. 2004, 13, 16–17.
77. Dai, J.; Miller, A.H.; Bremner, J.D.; Goldberg, J.; Jones, L.; Shallenberger, L.; Vaccarino, V. Adherence to the Mediterranean diet is inversely associated with circulating interleukin-6 among middle-aged men: A twin study. Circulation 2008, 117, 169.
78. Milaneschi, Y.; Bandinelli, S.; Penninx, B.W.; Vogelzangs, N.; Corsi, A.M.; Lauretani, F.; Kisialiou, A.; Vazzana, R.; Terracciano, A.; Guralnik, J.M.; et al. Depressive symptoms and inflammation increase in a prospective study of older adults: A protective effect of a healthy (Mediterranean-style) diet. Mol. Psychiatry 2010, 16, 589–590.
79. Fontana, L. Neuroendocrine factors in the regulation of inflammation: Excessive adiposity and calorie restriction. Exp. Gerontol. 2009, 44, 41–45.
80. Lutter, M.; Krishnan, V.; Russo, S.J.; Jung, S.; McClung, C.A.; Nestler, E.J. Orexin Signaling Mediates the Antidepressant-Like Effect of Calorie Restriction. J. Neurosci. 2008, 28, 3071–3075.
81. Chaix, A.; Zarrinpar, A.; Miu, P.; Panda, S. Time-restricted feeding is a preventative and therapeutic intervention against diverse nutritional challenges. Cell Metab. 2014, 20, 991–1005.
82. Fond, G.; MacGregor, A.; Leboyer, M.; Michalsen, A. Fasting in mood disorders: Neurobiology and effectiveness. A review of the literature. Psychiatry Res. 2013, 209, 253–258.
83. Rangel-Huerta, O.D.; Aguilera, C.M.; Mesa, M.D.; Gil, A. Omega-3 long-chain polyunsaturated fatty acids supplementation on inflammatory biomakers: A systematic review of randomised clinical trials. Br. J. Nutr. 2012, 107, S159–S170.
84. Appleton, K.M.; Rogers, P.J.; Ness, A.R. Updated systematic review and meta-analysis of the effects of n−3 long-chain polyunsaturated fatty acids on depressed mood. Am. J. Clin. Nutr. 2010, 91, 757–770.
85. Bloch, M.H.; Hannestad, J. Omega-3 fatty acids for the treatment of depression: Systematic review and meta-analysis. Mol. Psychiatry 2011, 17, 1272–1282.
86. Baune, B.; Smith, E.; Reppermund, S.; Air, T.; Samaras, K.; Lux, O.; Brodaty, H.; Sachdev, P.; Trollor, J. Inflammatory biomarkers predict depressive, but not anxiety symptoms during aging: The prospective Sydney Memory and Aging Study. Psychoneuroendocrinology 2012, 37, 1521–1530.
87. Gimeno, D.; Kivimäki, M.; Brunner, E.J.; Elovainio, M.; De Vogli, R.; Steptoe, A.; Kumari, M.; Lowe, G.D.; Rumley, A.; Marmot, M.G.; et al. Associations of C-reactive protein and interleukin-6 with cognitive symptoms of depression: 12-year follow-up of the Whitehall II study. Psychol. Med. 2008, 39, 413–423.
88. Andrés-Rodríguez, L.; Borràs, X.; Feliu-Soler, A.; Pérez-Aranda, A.; Rozadilla-Sacanell, A.; Arranz, B.; Montero-Marin, J.; García-Campayo, J.; Angarita-Osorio, N.; Maes, M.; et al. Machine Learning to Understand the Immune-Inflammatory Pathways in Fibromyalgia. Int. J. Mol. Sci. 2019, 20, 4231.
89. Ironside, M.; Admon, R.; Maddox, S.A.; Mehta, M.; Douglas, S.; Olson, D.P.; Pizzagalli, D.A. Inflammation and depressive phenotypes: Evidence from medical records from over 12 000 patients and brain morphology. Psychol. Med. 2019, 1–9.
90. Angst, J.; Sellaro, R.; Stassen, H.H.; Gamma, A. Diagnostic conversion from depression to bipolar disorders: Results of a long-term prospective study of hospital admissions. J. Affect. Disord. 2005, 84, 149–157.
91. Holmskov, J.; Licht, R.W.; Andersen, K.; Stage, K.B.; Nilsson, F.M.; Valentin, J.; Bech, P.; Nielsen, R.E.; Stage, T.B. Diagnostic Conversion to Bipolar Disorder in Unipolar Depressed Patients Participating in Trials on Antidepressants. Eur. Psychiatry 2016, 40, 76–81.
92. Modabbernia, A.; Taslimi, S.; Brietzke, E.; Ashrafi, M. Cytokine Alterations in Bipolar Disorder: A Meta-Analysis of 30 Studies. Biol. Psychiatry 2013, 74, 15–25.
93. Munkholm, K.; Braüner, J.V.; Kessing, L.V.; Vinberg, M. Cytokines in bipolar disorder vs. healthy control subjects: A systematic review and meta-analysis. J. Psychiatr. Res. 2013, 47, 1119–1133.
94. Wollenhaupt-Aguiar, B.; Librenza-Garcia, D.; Bristot, G.; Przybylski, L.; Stertz, L.; Burque, R.K.; Ceresér, K.M.; Spanemberg, L.; Caldieraro, M.A.; Frey, B.N.; et al. Differential biomarker signatures in unipolar and bipolar depression: A machine learning approach. Aust. N. Z. J. Psychiatry 2019, 54, 393–401.
95. Poletti, S.; Vai, B.; Mazza, M.G.; Zanardi, R.; Lorenzi, C.; Calesella, F.; Cazzetta, S.; Branchi, I.; Colombo, C.; Furlan, R.; et al. A peripheral inflammatory signature discriminates bipolar from unipolar depression: A machine learning approach. Prog. Neuro Psychopharmacol. Biol. Psychiatry 2021, 105, 110136.
96. Zheng, Y.; He, S.; Zhang, T.; Lin, Z.; Shi, S.; Fang, Y.; Jiang, K.; Liu, X. Detection Study of Bipolar Depression Through the Application of a Model-Based Algorithm in Terms of Clinical Feature and Peripheral Biomarkers. Front. Psychiatry 2019, 10, 266.
97. Walss-Bass, C.; Suchting, R.; Olvera, R.L.; Williamson, D.E. Inflammatory markers as predictors of depression and anxiety in adolescents: Statistical model building with component-wise gradient boosting. J. Affect. Disord. 2018, 234, 276–281.
98. Cameron, H.A.; Hazel, T.G.; McKay, R.D. Regulation of neurogenesis by growth factors and neurotransmitters. J. Neurobiol. 1998, 36, 287–306.
99. Klein, S.L.; Flanagan, K.L. Sex differences in immune responses. Nat. Rev. Immunol. 2016, 16, 626–638.
100. Arnold, S.E.; Initiative, F.T.A.D.N.; Xie, S.X.; Leung, Y.-Y.; Wang, L.-S.; Kling, M.A.; Han, X.; Kim, E.J.; A Wolk, D.; A Bennett, D.; et al. Plasma biomarkers of depressive symptoms in older adults. Transl. Psychiatry 2012, 2, e65.
101. Wieser, V.; Moschen, A.R.; Tilg, H. Inflammation, Cytokines and Insulin Resistance: A Clinical Perspective. Arch. Immunol. Ther. Exp. 2013, 61, 119–125.